Intercept Pharmaceuticals, Inc. Logo
 
Press Releases
Date Title and Summary View
Dec 9, 2016 NEW YORK, Dec. 09, 2016 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced management will be participating in following investor conference: ...
Nov 11, 2016 NEW YORK, Nov. 11, 2016 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced results from three new exploratory analyses of the Phase 3 POISE trial of ...
Nov 3, 2016 Net Ocaliva® (obeticholic acid or OCA) 3Q sales of $4.7 million Positive opinion adopted by Committee of Medicinal Products in Human Use (CHMP) for Ocaliva in Primary Biliary Cholangitis (PBC) in EUEnrollment in Phase 2 CONTROL tr...
Nov 1, 2016 NEW YORK, Nov. 01, 2016 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat non-viral, progressive liver diseases, today announced multiple Ocaliva® (obeticholic acid) for PBC and INT-767 data...
Oct 28, 2016 NEW YORK, Oct. 28, 2016 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat non-viral, progressive liver diseases, today announced that it will report its third quarter 2016 financial results prior to the NASDAQ market o...
Oct 14, 2016 NEW YORK, Oct. 14, 2016 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat non-viral, progressive liver diseases, today announced that the European Medicines Agency's (EMA) Committee for Medicin...
Sep 19, 2016 New Drug Submission filed to Health Canada for obeticholic acid for PBCSubmission granted priority reviewIf approved, obeticholic acid would represent first new treatment option for PBC in 20 years                      &...
Sep 2, 2016 NEW YORK, Sept. 02, 2016 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat non-viral, progressive liver diseases, today announced management will be participating in the following investor conferences: ...
Aug 17, 2016 NEW YORK, Aug. 17, 2016 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat non-viral, progressive liver diseases, today announced that the ...
Aug 4, 2016 Ocaliva® (obeticholic acid or OCA) approved by the FDA under the accelerated approval pathway on May 27, 2016Net Ocaliva 2Q sales of $75,000 shipped to patients, $2.7 million recorded as deferred revenueREGENERATE NASH trial tar...
Page:
1
... NextLast
= add release to Briefcase